Source: Annual Congress 2001 - COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. M. A. Calverley, S. Burge, S. Spencer, J. Anderson, P. W. Jones (Liverpool, Birmingham, London, United Kingdom). Day to day variation in bronchodilator reversibility in stable COPD. Eur Respir J 2001; 16: Suppl. 31, 3250

Member's Comments

No comment yet.

Related content which might interest you: The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002 The effect of single dose inhaled budesonide on Amppc20 in patients with mild asthma: a 3 month follow up Source: Eur Respir J 2005; 26: Suppl. 49, 369s Year: 2005 Effects of switching inhaled medication from twice a day to once a day in patients with bronchial asthma Source: International Congress 2016 – Asthma points to ponder Year: 2016 Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Bronchodilator reversibility - differences between asthma and COPD Source: International Congress 2019 – Respiratory function assessment in disease Year: 2019 Superior spirometric efficacy of single dose formoterol compared to single dose salmeterol during the first hour post-dose in moderate and severe COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 57s Year: 2001 Formoterol given either alone or together with tiotropium, reduces the rate of exacerbations in stable COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006 REVERDIL study: validity of salbutamol in determining COPD reversibility prior to formoterol treatment Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003 The effect of bronchodilation on symptom time course during exercise in COPD Source: Annual Congress 2010 - Thoracic dynamics and dyspnoea on exercise Year: 2010 Reproducibility of reversibility in airflow limitation over a year in clinically stable COPD Source: Eur Respir J 2005; 26: Suppl. 49, 62s Year: 2005 No evidence for increase in serious asthma exacerbations with formoterol 24 μg twice daily Source: Eur Respir J 2005; 26: Suppl. 49, 51s Year: 2005 Optimizing baseline constant work rate exercise test duration for COPD bronchodilator studies Source: Virtual Congress 2020 – Exploring exercise responses in respiratory diseases Year: 2020 Influence of basal FEV1 on the response to bronchodilator agents in COPD Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001 Bronchodilator reversibility and short-term inhaled corticosteroid response in Japanese patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004 Nebulized bronchodilator therapy in stable COPD – effect on quality of life and spirometry Source: Eur Respir J 2006; 28: Suppl. 50, 64s Year: 2006 Montelukast can improve isolated nocturnal hypoxemia in stable COPD patients with positive reversibility test Source: Eur Respir J 2006; 28: Suppl. 50, 427s Year: 2006 The effect of long-term administration of inhaled formoterol on VO2 max of COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 322s Year: 2004 Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Indacaterol once-daily provides significant bronchodilation irrespective of baseline reversibility in COPD patients Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Emphysema phenotype predicts pattern of exercise response to bronchodilators in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 109s Year: 2005